Stockreport

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

OS Therapies Incorporated  (OSTX) 
PDF Company now listeria-based cancer immunotherapy world leaderExpands clinical pipeline with 3 new cancer immunotherapy candidates8 pre-clinical immunotherapy candidates t [Read more]